HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases.

AbstractAIM:
The aim of this study was to assess the usefulness of (153)samarium-ethylene-diamino-tetramethylene phosphonic acid ((153)Sm-EDTMP, a beta and gamma emitter) treatment in the palliation of painful bone metastases from breast cancer.
PATIENTS AND METHODS:
43 women (aged 41-79, mean 60 years) with bone-disseminated breast cancer and bone pain refractory to opioid analgesics received (153)Sm-EDTMP. Karnofsky performance status, pain score (numeric rating scale), analgesic score (World Health Organisation) and blood count were evaluated before treatment and 1 and 3 months after the treatment.
RESULTS:
Significant pain relief was observed in 51 and 42% of the patients, mild relief in 30 and 30%, and no effect in 19 and 28% of the patients 1 and 3 months after administration, respectively. Mild and transient bone marrow suppression was observed as a side effect of (153)Sm-EDTMP treatment. None of the patients showed grade 4 haematological toxicity and only 1 patient showed grade 3 (National Cancer Institute common toxicity criteria). The majority of patients had grade 1 or 2 haematological toxicity.
CONCLUSION:
(153)Sm-EDTMP treatment is effective and safe in bone pain palliation in breast cancer. 3 months after administering (153)Sm-EDTMP, pain relief to varying degrees was observed in 72% of patients.The haematological toxicity after (153)Sm-EDTMP treatment was mild and transient.
AuthorsJiri Dolezal
JournalOnkologie (Onkologie) Vol. 32 Issue 1-2 Pg. 35-9 (Feb 2009) ISSN: 1423-0240 [Electronic] Switzerland
PMID19209017 (Publication Type: Clinical Trial, Journal Article)
CopyrightCopyright (c) 2009 S. Karger AG, Basel.
Chemical References
  • Organometallic Compounds
  • Organophosphorus Compounds
  • Radiopharmaceuticals
  • samarium Sm-153 lexidronam
Topics
  • Adult
  • Aged
  • Bone Marrow Diseases (diagnosis, etiology)
  • Bone Neoplasms (complications, radiotherapy, secondary)
  • Breast Neoplasms (radiotherapy)
  • Female
  • Humans
  • Middle Aged
  • Organometallic Compounds (adverse effects, therapeutic use)
  • Organophosphorus Compounds (adverse effects, therapeutic use)
  • Pain (etiology, prevention & control)
  • Pain Measurement (radiation effects)
  • Radiation Injuries (diagnosis, etiology)
  • Radiopharmaceuticals (adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: